Patents Assigned to Axelar AB
  • Picropodophyllin polymorph C and its use in cancer therapy
    Patent number: 9314525
    Abstract: The invention relates to novel polymorphs of picropodophyllin, methods for preparing said polymorphs and pharmaceutical compositions comprising said polymorphs, as well as the use of said polymorphs in therapy such as cancer therapy.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: April 19, 2016
    Assignee: Axelar AB
    Inventors: Mikael Bisrat, Magnus Brisander
  • Picropodophyllin Monohydrate or Polymorph A in Cancer Therapy
    Publication number: 20130331445
    Abstract: The invention related to picropodophyllin monohydrate as well as to picropodophyllin polymorph A for use in therapy, such as their use in cancer therapy.
    Type: Application
    Filed: October 7, 2011
    Publication date: December 12, 2013
    Applicant: Axelar AB
    Inventors: Mikael Bisrat, Magnus Brisander
  • Picropodophyllin Polymorphs B or C for Use in Cancer Therapy
    Publication number: 20130317099
    Abstract: The invention relates to novel polymorphs of picropodophyllin, methods for preparing said polymorphs and pharmaceutical compositions comprising said polymorphs, as well as the use of said polymorphs in therapy such as cancer therapy.
    Type: Application
    Filed: October 7, 2011
    Publication date: November 28, 2013
    Applicant: Axelar AB
    Inventors: Mikael Bisrat, Magnus Brisander
  • New Process for Preparing Cyclolignans
    Publication number: 20130245285
    Abstract: The invention relates to a one-pot reaction for the preparation of a compound of Formula (I). The compound of Formula (I) may be further transformed into picropodophyllin and derivatives thereof.
    Type: Application
    Filed: August 30, 2011
    Publication date: September 19, 2013
    Applicant: AXELAR AB
    Inventors: Magnus Axelsson, Ulf Bremberg, Auri Linden, Fredrik Von Kieseritzky
  • Use of specific cyklolignans
    Patent number: 8389747
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: March 5, 2013
    Assignee: Axelar AB
    Inventors: Olle Larsson, Magnus Axelson
  • USE OF CYCLOLIGNANS FOR THE TREATMENT OF A HYPERACTIVE IMMUNE SYSTEM
    Publication number: 20110178050
    Abstract: There is disclosed use of certain picro derivatives of cyclolignans for prophylaxis or treatment of diseases or conditions characterised by a hyperactive immune system. Examples of cyclolignans according to the invention include picropodophyllin, deoxypicropodophyllin, anhydropicropodophyllol or deoxyanhydropicropodophyllol.
    Type: Application
    Filed: June 18, 2009
    Publication date: July 21, 2011
    Applicant: Axelar AB
    Inventors: Magnus Axelson, Olle Larsson
  • USE OF CYCLOLIGNANS FOR THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
    Publication number: 20100227797
    Abstract: There is disclosed use of certain cyclolignans for prophylaxis or treatment of diabetes mellitus type 2, nephropathy, retinopathy, macular degeneration, retinopathy of prematurity, central retinal vein occlusion, branch retinal vein occlusion, rubeotic glaucoma, thyroid eye disease, corneal graft rejection and corneal chemical burns; and for contraception. Preferred compounds are picropodophyllin, deoxypicropodophyllin and anhydropicropodophyllol. There is also described a method of treatment of an eye disease.
    Type: Application
    Filed: February 23, 2007
    Publication date: September 9, 2010
    Applicant: AXELAR AB
    Inventors: Magnus Axelson, Olof Danielsson, Mario-Alexander Economou, Olle Larsson
  • NEW USE OF SPECIFIC CYKLOLIGNANS
    Publication number: 20100216728
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Application
    Filed: February 26, 2010
    Publication date: August 26, 2010
    Applicant: AXELAR AB
    Inventors: Olle LARSSON, Magnus Axelson
  • Use of specific cyklolignans
    Patent number: 7662851
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: February 16, 2010
    Assignee: Axelar AB
    Inventors: Olle Larsson, Magnus Axelson
  • USE OF SPECIFIC CYKLOLIGNANS
    Publication number: 20090326248
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Application
    Filed: July 23, 2009
    Publication date: December 31, 2009
    Applicant: AXELAR AB
    Inventors: Olle LARSSON, Magnus Axelson
  • Use of specific cyklolignans
    Patent number: 7629381
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Grant
    Filed: January 29, 2008
    Date of Patent: December 8, 2009
    Assignee: Axelar AB
    Inventors: Olle Larsson, Magnus Axelson
  • USE OF SPECIFIC CYKLOLIGNANS
    Publication number: 20080221207
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Application
    Filed: January 29, 2008
    Publication date: September 11, 2008
    Applicant: AXELAR AB
    Inventors: Olle LARSSON, Magnus Axelson
  • USE OF SPECIFIC CYKLOLIGNANS
    Publication number: 20080119528
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Application
    Filed: January 29, 2008
    Publication date: May 22, 2008
    Applicant: AXELAR AB
    Inventors: Olle LARSSON, Magnus Axelson
  • Use of cyclolignans
    Patent number: 7348358
    Abstract: The invention refers to the use of specific cyclolignans, wherein the carbon atoms in positions 9 and 9? have cis configuration, for inhibition of the insulin-like growth factor-1 receptor. Said compounds can be used for treatment of IGF-1R dependent diseases, such as cancer, psoriasis, artherosclerosis and acromegaly. A preferred compound is picropodophyllin.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: March 25, 2008
    Assignee: Axelar AB
    Inventors: Olle Larsson, Magnus Axelson
  • Use of cyklolignans and new cyklolignans
    Publication number: 20060154982
    Abstract: Compounds which inhibit the insulin-like growth factor-1 receptor (IGF-1 R) and methods for using them for treating IGF- 1 R dependent diseases, such as cancer.
    Type: Application
    Filed: February 3, 2006
    Publication date: July 13, 2006
    Applicant: AXELAR AB
    Inventors: Olle Larsson, Magnus Axelson